Physician profile
Stephen M Scott
NPI 1154365203
$2,621.09
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $619 · 2021: $834 · 2022: $462.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $376.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $356.82 | 2019-2021 | |
| Novo Nordisk INC | $271.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $164.45 | 2019-2022 | |
| Pfizer INC. | $159.58 | 2019-2022 | |
| Amarin Pharma, INC. | $124.71 | 2019-2022 | |
| Amgen INC. | $109.93 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $95.84 | 2019-2022 | |
| Lilly USA, LLC | $95.58 | 2019-2022 | |
| Abbvie INC. | $93.20 | 2019-2022 | |
| Genentech USA, INC. | $75.29 | 2019-2020 | |
| Alkermes, INC. | $57.49 | 2019-2021 | |
| Abbott Laboratories | $56.69 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.58 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.19 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.15 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $29.08 | 2021 | |
| Allergan, INC. | $24.60 | 2020 | |
| Daiichi Sankyo INC. | $21.52 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.66 | 2020 | |
| Gilead Sciences, INC. | $17.73 | 2021 | |
| Mdd US Operations, LLC | $16.54 | 2019 | |
| Corcept Therapeutics | $15.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.00 | 2022 | |
| Merck Sharp & Dohme LLC | $12.98 | 2021 | |
| Bausch Health US, LLC | $12.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.